Benzinga

Benzinga

Benzinga

miércoles, agosto 19

Sutro Biopharma Inc

STRONASDAQ
Trade with Public
Trade with Public
$21.91
-0.13-0.59%
al cierre: Aug 19, 5:00 PM EST
$21.91
N/A
After hour: 4:00 PM EST
Ganancias: Los beneficios de Q2 2026 se publicaron el mié ago 12th, antes de la apertura del mercado
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Sutro Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sutro Biopharma (STRO).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

2S.Buy
10Buy
1Hold
1Sell
Consensus RatingBuy# Analysts14Avg. Consensus PT$27Upside to Avg. PT+21.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 13, 2026CitizensReni J. BenjaminPT CutMarket Outperform$41→$34
Aug 13, 2026WedbushDavid NierengartenMaintainedOutperform$60
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34

Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and lowers the price target from $41 to $34.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $60 price target.
Benzinga Newsdesk

PRO
Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50

Truist Securities analyst Supawat Thongthip assumes Sutro Biopharma (NASDAQ:STRO) with a Buy rating and announces Price Target of $50.
Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56

Barclays analyst Lukas Shumway initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Overweight rating and announces Price Target of $56.
Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Sutro Biopharma, Raises Price Target to $43

Leerink Partners maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and raises the price target from $38 to $43.
Benzinga Newsdesk

PRO
Wedbush Upgrades Sutro Biopharma to Outperform, Raises Price Target to $60

Wedbush analyst David Nierengarten upgrades Sutro Biopharma (NASDAQ:STRO) from Neutral to Outperform and raises the price target from $22 to $60.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved